Alvotech develops and manufactures biosimilar medicines for global markets. Company news centers on its approved and marketed biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, along with disclosed candidates for autoimmune disorders, eye disorders, osteoporosis, respiratory disease and cancer.
Recurring updates cover financial results, annual reporting, FDA interactions tied to the Reykjavik manufacturing facility, biosimilar study results such as AVT80, supply and commercialization partnerships, intellectual-property settlements, executive changes and manufacturing-platform developments. Alvotech also reports on global commercial reach through partners across the United States, Europe, Japan, China and other international markets.
Alvotech (ALVO) has announced its upcoming Annual General Meeting (AGM) scheduled for June 25, 2025, at 09:00 a.m. CEST. The meeting will take place at Arendt & Medernach's premises in Luxembourg. Shareholders can access the complete agenda and meeting materials through Alvotech's investor relations website. The company has provided a dedicated contact for investor relations inquiries through Benedikt Stefansson, VP.
Alvogen Lux Holdings S.ár.l., Alvotech's second-largest shareholder, has acquired 95,000 shares of Alvotech (ALVO) at ISK 1,260 per share on May 20, 2025. The transaction was reported to the Luxembourg Commission de Surveillance du Secteur Financier (CSSF). Alvogen Lux Holdings' ownership structure consists of CVC (40%), Aztiq (30%), and Temasek (20%) as its largest shareholders.
Alvotech (NASDAQ: ALVO) has signed an agreement with DNB Carnegie Investment Bank AB to provide liquidity services for its Swedish Depository Receipts (SDRs) trading on Nasdaq Stockholm. Starting May 20, 2025, DNB Carnegie will act as a liquidity provider, continuously quoting prices for Alvotech's SDRs in compliance with Nasdaq Stockholm's minimum requirements. The primary objective is to enhance SDR liquidity and minimize the spread between buying and selling prices.
Alvotech (ALVO) reported that Richard Davies, Deputy Chairman of the Board of Directors, has acquired 19,988 shares at a price of $10.18 per share on May 14, 2025. The total transaction value amounts to approximately $203,477. The transaction was filed with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) as part of the required disclosure for transactions of managers and closely associated persons.
Alvogen Lux Holdings S.ár.l., Alvotech's (ALVO) second-largest shareholder, has acquired 210,000 shares at ISK 1,277.38 per share. The transaction was reported through a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF). Alvogen Lux Holdings' ownership structure consists of CVC (40%), Aztiq (30%), and Temasek (20%) as its largest shareholders.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has announced its participation in the BofA Securities Healthcare Conference 2025 in Las Vegas from May 13-15, 2025. The company's management team will conduct one-on-one meetings and participate in a fireside chat on May 14, 2025, from 11:40 am to 12:10 pm EDT. A live audio webcast of the chat will be available to the public through Alvotech's investor relations website, with a replay accessible for 90 days post-event.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in the BofA Securities Healthcare Conference 2025 in Las Vegas from May 13-15, 2025. The company's management team will conduct one-on-one meetings and participate in a fireside chat on May 14, 2025, at 11:40 am-12:10 pm EDT. The chat will be accessible via live audio webcast on Alvotech's investor relations website, with a replay available for 90 days post-event.